2 completed, 1 terminated. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Faraday Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation in STEMI Patients Using FDY-5301 FDY-5301, Placebo - Acute Myocardial Infarction, STEMI | Phase 3 | Completed | Faraday Pharmaceuticals, Inc. | 2351 | 2022-05-02 | 2025-09-12 |
| Evaluation of FDY-5301 in Major Trauma Patients in ICU FDY-5301, Placebo - ICU Acquired Weakness | Phase 2 | Terminated | Faraday Pharmaceuticals, Inc. | 8 | 2021-09-20 | 2023-06-13 |
| A Study of Acute Myocardial Infarction Using FDY-5301 FDY-5301, Placebo - Acute Myocardial Infarction, STEMI | Phase 2 | Completed | Faraday Pharmaceuticals, Inc. | 120 | 2017-10-27 | 2026-01-16 |
ST Elevation Myocardial Infarction (2) · Asthenia (1) · Muscular Atrophy (1)
Sodium Chloride (1)
United States (3) · Hungary (2) · Poland (2) · Canada (1) · Israel (1) · Portugal (1) · United Kingdom (1)